There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Capricor Therapeutics (CAPR – Research Report) and Amylyx Pharmaceuticals Inc (AMLX – Research Report) with bullish sentiments.
Capricor Therapeutics (CAPR)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Capricor Therapeutics, with a price target of $18.00. The company’s shares closed last Tuesday at $3.73.
According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Capricor Therapeutics with a $15.00 average price target, a 317.8% upside from current levels. In a report issued on June 28, Maxim Group also assigned a Buy rating to the stock with a $12.00 price target.
Amylyx Pharmaceuticals Inc (AMLX)
In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Amylyx Pharmaceuticals Inc, with a price target of $35.00. The company’s shares closed last Tuesday at $19.50.
According to TipRanks.com, Fein has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Amylyx Pharmaceuticals Inc with a $33.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CAPR: